Technical Analysis for RNXT - RenovoRx, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.37 | 5.38% | 0.07 |
RNXT closed up 5.38 percent on Wednesday, May 8, 2024, on 35 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| 180 Bullish Setup | Bullish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 12 hours ago |
| Rose Above Previous Day's High | about 12 hours ago |
| Rose Above 200 DMA | about 12 hours ago |
| Outside Day | about 12 hours ago |
| Up 3% | about 12 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trial for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatment Pancreatic Cancer Oncolytics Biotech Gastrointestinal Cancer Evofosfamide Gemcitabine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatment Pancreatic Cancer Oncolytics Biotech Gastrointestinal Cancer Evofosfamide Gemcitabine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.29 |
| 52 Week Low | 0.5488 |
| Average Volume | 41,592 |
| 200-Day Moving Average | 1.32 |
| 50-Day Moving Average | 1.36 |
| 20-Day Moving Average | 1.23 |
| 10-Day Moving Average | 1.25 |
| Average True Range | 0.11 |
| RSI (14) | 59.84 |
| ADX | 18.69 |
| +DI | 22.26 |
| -DI | 13.29 |
| Chandelier Exit (Long, 3 ATRs) | 1.04 |
| Chandelier Exit (Short, 3 ATRs) | 1.44 |
| Upper Bollinger Bands | 1.33 |
| Lower Bollinger Band | 1.12 |
| Percent B (%b) | 1.19 |
| BandWidth | 17.13 |
| MACD Line | 0.00 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0238 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.49 | ||||
| Resistance 3 (R3) | 1.48 | 1.42 | 1.47 | ||
| Resistance 2 (R2) | 1.42 | 1.39 | 1.43 | 1.46 | |
| Resistance 1 (R1) | 1.40 | 1.37 | 1.41 | 1.41 | 1.46 |
| Pivot Point | 1.34 | 1.34 | 1.35 | 1.35 | 1.34 |
| Support 1 (S1) | 1.32 | 1.31 | 1.33 | 1.33 | 1.28 |
| Support 2 (S2) | 1.26 | 1.29 | 1.27 | 1.28 | |
| Support 3 (S3) | 1.24 | 1.26 | 1.27 | ||
| Support 4 (S4) | 1.25 |
